NVDA+0.84%AAPL−2.51%GOOGL−1.17%MSFT−2.04%AMZN−0.15%TSM+2.85%SPCX−1.20%AVGO+0.21%
StockVS

NASDAQ · Biotechnology · USD

Mineralys Therapeutics, Inc. (MLYS) Stock Analysis

Mineralys Therapeutics, Inc. (MLYS) is a Biotechnology stock listed on NASDAQ and quoted in US Dollar.

MLYS

$28.21

−$0.06 (−0.21%)

Sep 4, 2026 · Market close

Compare

Price History

Hover for the daily close. The dotted line marks the period open.

Compare MLYS with… →

MLYS Key Statistics

As of Sep 4, 2026
Trading
Open
$28.00
Previous Close
$28.27
Day's Range
27.40–28.35
52-Week Range
22.30–47.65
Volume
643.00K
BetaHow much the share price moves relative to the wider market. 1.0 moves in line with it; above 1.0 swings more, below 1.0 less.
0.68
Valuation
Market Cap
$2.49B
P/E Ratio
unprofitable
EPS (ttm)Profit attributable to each share over the last twelve months.
−4.20
Financials (FY)
Revenue (FY)
$0.00
Net Income (FY)
−$154.65M
Profit marginThe share of revenue left as profit after all costs and taxes.
0.00%
Shares OutstandingThe total number of shares held by all investors. Market value is this figure multiplied by the share price.
88.41M
1-Year Return
−14.82%
Dividend and dates
Earnings Date
November 10, 2026estimated
Avg Volume
1.18M

Only metrics the company reports are shown. Data provided by Yahoo Finance via yfinance. Updated daily.

MLYS Stock Return by Calendar Year

Calendar-year returns computed from daily closing prices. Partial years are shown muted and marked with an asterisk.

YearReturn
2026 (partial year)−22.27%
2025+194.80%
2024+43.14%
2023 (partial year)−53.36%

As of September 4, 2026.

MLYS Revenue and Earnings by Fiscal Year

FY ends December
Fiscal yearRevenueNet incomeNet margin
2025$0.00−$154.65M—
2024$0.00−$177.81M—
2023$0.00−$71.90M—
2022$0.00−$29.80M—
Fiscal yearRevenueGross profitOperating incomeNet incomeNet margin
2025$0.00—−$170.60M−$154.65M—
2024$0.00—−$192.40M−$177.81M—
2023$0.00—−$84.66M−$71.90M—
2022$0.00—−$31.48M−$29.80M—

Annual figures as reported, in the company's reporting currency. As of December 31, 2025.

MLYS Valuation vs Biotechnology Median

Median of 656 stocks
MetricMLYSBiotechnology medianvs median
Profit margin0.00%0.00%0.0 pts above

Medians across 656 Biotechnology stocks that report the metric. Medians, not averages, so one outlier cannot move them. As of September 4, 2026.

Recent News

News provided by third-party sources. Not financial advice.

Analysis

Data-derived

Company Overview

Mineralys Therapeutics, Inc. (MLYS) is capitalised at $2.49B on the latest close. It is classified in the Biotechnology industry, within the Healthcare sector. The company reports 76 employees.

The most recent close on file for MLYS is $28.21, dated September 4, 2026. That is −$0.06 (−0.21%) against the previous close. Over the past 52 weeks the price has ranged from $22.30 to $47.65. The latest close sits 26.5% above that 52-week low.

Financial Health

Fiscal 2025 revenue came to $0.00. The same year closed with a net loss of $154.65M. Profit margin runs at 0%. Trailing earnings per share are −4.2.

Across the 4 fiscal years on file, revenue moves from $0.00 in 2022 to $0.00 in 2025. Of those 4 years, 0 report positive net income.

Valuation Assessment

The record shows negative trailing earnings, so no price-to-earnings ratio is published.

Over the trailing twelve months the price has returned −14.82%. Across 3 years the annualized return works out at +29.73%. The reported beta is 0.68. Annualized volatility over the trailing 3 years is 85.29%.

Growth & Income

The record shows no dividend for MLYS.

Across the complete calendar years on file, 2025 returned +194.80% and 2024 returned +43.14%. So far in 2026 the price is −22.27%.

Peer Comparison

Mineralys Therapeutics, Inc. (MLYS) operates in the Biotechnology industry. Here is how it compares to its closest peers by market capitalization:

Company Ticker Market Cap P/E Ratio
Mineralys Therapeutics, Inc. MLYS $2.49B —
Vertex Pharmaceuticals Incorporated VRTX $138.42B 32.5
Regeneron Pharmaceuticals, Inc. REGN $85.22B 20.5
argenx SE ARGX $64.25B 40.1

The Biotechnology industry average P/E ratio is 12.6x. Mineralys Therapeutics, Inc. has no P/E ratio because it is not currently profitable.

Every figure above is read from this page's own data on each nightly rebuild. Informational only, not financial advice. As of September 4, 2026.

Related Biotechnology Stocks

VRTX

Vertex Pharmaceuticals Incorporated

$138.42B

 REGN

Regeneron Pharmaceuticals, Inc.

$85.22B

 ARGX

argenx SE

$64.25B

 MRNA

Moderna, Inc.

$58.11B

 RVMD

Revolution Medicines, Inc.

$45.01B

 ONC

BeOne Medicines AG

$40.53B
View all Biotechnology stocks →

Popular Healthcare Stocks

LLY

Eli Lilly and Company

$1.02T

 JNJ

Johnson & Johnson

$663.28B

 ABBV

AbbVie Inc.

$453.19B

 MRK

Merck & Co., Inc.

$370.89B

 UNH

UnitedHealth Group Incorporated

$356.47B
View all Healthcare stocks →

About Mineralys Therapeutics, Inc.

Mineralys Therapeutics, Inc., a biopharmaceutical company, develops medicines to target diseases driven by dysregulated aldosterone in the United States. It is developing lorundrostat, a proprietary, orally administered, highly selective aldosterone synthase inhibitor for the treatment of cardiorenal conditions affected by dysregulated aldosterone, such as hypertension, chronic kidney disease, and obstructive sleep apnea. The company was formerly known as Catalys SC1, Inc. and changed its name to Mineralys Therapeutics, Inc. in May 2020. Mineralys Therapeutics, Inc. was incorporated in 2019 and is headquartered in Radnor, Pennsylvania.

Visit website →